60 Degrees Pharmaceuticals announced it has signed clinical trial agreements with all three of the planned clinical trial sites for the Tafenoquine for Babesiosis study now enrolling. Tufts Medical Center, Yale University, and Rhode Island Hospital will conduct the world’s first randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. At least 24, and potentially up to 33, hospitalized patients diagnosed with relapsing babesiosis will be recruited for the study, with interim results anticipated by September, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
- 60 Degrees Pharmaceuticals files $15M mixed securities shelf
- 60 Degrees Pharmaceuticals’ study of tafenoquine in babesiosis approved
- 60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
- 60 Degrees announces first patient enrolled in clinical trial of Tafenoquine